National Cancer Institute (NCI): Thymoma trials

The registry lists 14 Thymoma studies with National Cancer Institute (NCI) as lead sponsor. 3 are open to participants now and 6 have results posted.

Phase 1 4Phase 2 10No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaRecruitingNCT06885697Phase 1
• PT-112 in Subjects With Thymoma and Thymic CarcinomaRecruitingNCT05104736Phase 2
• Tissue Procurement and Natural History Study of Patients With Malignant MesotheliomaRecruitingNCT01950572
• Sunitinib for Advanced Thymus Cancer Following Earlier TreatmentCompletedNCT01621568Phase 2Results posted
• Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic MalignanciesCompletedNCT01306045Phase 2Results posted
• A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, MalignanciesTerminatedNCT01100944Phase 1/2Results posted
• Multicenter Phase II Study of IMC-A12 in Patients With Thymoma and Thymic Carcinoma Who Have Been Previously Treated With ChemotherapyCompletedNCT00965250Phase 2Results posted
• Saracatinib in Treating Patients With Relapsed or Refractory Thymoma or Thymic CancerTerminatedNCT00718809Phase 2Results posted
• Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced StageCompletedNCT00589290Phase 2Results posted
• Bintrafusp Alfa (M7824) in Subjects With Thymoma and Thymic CarcinomaActive, not recruitingNCT04417660Phase 2
• A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingNCT03076554Phase 2
• 18F FLT Imaging Studies of Treatment Response for Lung Cancer and ThymomaWithdrawnNCT01610544Phase 2
• Tumor Cell Vaccines With ISCOMATRIX Adjuvant and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers and Malignant Pleural MesotheliomasTerminatedNCT01258868Phase 1
• Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural MesotheliomasTerminatedNCT01143545Phase 1